Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.13 (1y: -10%)
Market Cap 14.5 M P/E(ttm)
Enterprise Value 10.2 M P/B 2.20
MYOS- OTCPK (USA)
MYOS Corp
Not Rated
Top Ranked Predictable Companies
$0.13
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
MYOS's Cash to Debt is ranked higher than
99% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. MYOS: No Debt )
MYOS' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt
Equity to Asset 0.637
MYOS's Equity to Asset is ranked higher than
98% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. MYOS: 0.637 )
MYOS' s 10-Year Equity to Asset Range
Min: -0.54   Max: 0.64
Current: 0.64
-0.54
0.64
Z-Score: 17.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -332.80
MYOS's Operating margin (%) is ranked lower than
103% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. MYOS: -332.80 )
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.4   Max: -332.8
Current: -332.8
-4642.4
-332.8
Net-margin (%) -429.2
MYOS's Net-margin (%) is ranked lower than
98% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. MYOS: -429.2 )
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.5   Max: -429.2
Current: -429.2
-5653.5
-429.2
ROE (%) -63.1
MYOS's ROE (%) is ranked lower than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. MYOS: -63.1 )
MYOS' s 10-Year ROE (%) Range
Min: -1178.3   Max: -63.1
Current: -63.1
-1178.3
-63.1
ROA (%) -59.9
MYOS's ROA (%) is ranked lower than
118% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. MYOS: -59.9 )
MYOS' s 10-Year ROA (%) Range
Min: -199.3   Max: -59.9
Current: -59.9
-199.3
-59.9
ROC (Joel Greenblatt) (%) -1001.70
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
104% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. MYOS: -1001.70 )
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2626.3   Max: -1001.7
Current: -1001.7
-2626.3
-1001.7
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 2.20
MYOS's P/B is ranked lower than
54% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MYOS: 2.20 )
MYOS' s 10-Year P/B Range
Min: 1.6   Max: 15.67
Current: 2.2
1.6
15.67
P/S 11.50
MYOS's P/S is ranked lower than
110% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. MYOS: 11.50 )
MYOS' s 10-Year P/S Range
Min: 0   Max: 21.9
Current: 11.5
0
21.9
EV-to-EBIT 125
MYOS's EV-to-EBIT is ranked higher than
74% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. MYOS: 125 )
MYOS' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 1.7
Current: 125
0.1
1.7

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 4.3
MYOS's Price/Net Cash is ranked higher than
63% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. MYOS: 4.3 )
MYOS' s 10-Year Price/Net Cash Range
Min: 5.5   Max: 5.5
Current: 4.3
Price/Tangible Book 3.3
MYOS's Price/Tangible Book is ranked lower than
111% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. MYOS: 3.3 )
MYOS' s 10-Year Price/Tangible Book Range
Min: 4.4   Max: 4.4
Current: 3.3

Business Description


Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:
» More Articles for MYOS

Headlines

Articles On GuruFocus.com

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial